2016, Number 4
PDF size: 612.99 Kb.
ABSTRACTPrimary immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura and subsequently immune thrombocytopenic purpura) is an autoimmune disease in which there are antibodies against antigens of platelet surface, decreasing the platelet count and causing typical eruptions (purpura) and susceptibility to bleeding. It has been described for more than four centuries ago. Throughout history, their physiopathological mechanisms of immune type have allowed to reveal its features. In this literature review we describe the treatment options to provide tools for individualizing it. Also, consider the underlying conditions in a critical way is an integral part of decision making on the lines of therapy, which are very well defined at present.
GlaxoSmithKline. FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder. [Comunicado en Internet]. EE.UU: GlaxoSmithKline, 2008 Nov 20 [consultado: 2015 May 18]. Disponible en: http://web.archive. org/web/20101227031913/http://www.gsk.com/media/ pressreleases/2008/2008_pressrelease_10127.htm